APA

Rugo H. S., Finn R. S., Diéras V., Ettl J., Lipatov O., Joy A. A., Harbeck N., Castrellon A., Iyer S., Lu D. R., Mori A., Gauthier E. R., Bartlett C. H., Gelmon K. A. & Slamon D. J. (20190716). Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. : Breast cancer research and treatment.

Chicago

Rugo H S, Finn R S, Diéras V, Ettl J, Lipatov O, Joy A A, Harbeck N, Castrellon A, Iyer S, Lu D R, Mori A, Gauthier E R, Bartlett C Huang, Gelmon K A and Slamon D J. 20190716. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. : Breast cancer research and treatment.

Harvard

Rugo H. S., Finn R. S., Diéras V., Ettl J., Lipatov O., Joy A. A., Harbeck N., Castrellon A., Iyer S., Lu D. R., Mori A., Gauthier E. R., Bartlett C. H., Gelmon K. A. and Slamon D. J. (20190716). Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. : Breast cancer research and treatment.

MLA

Rugo H S, Finn R S, Diéras V, Ettl J, Lipatov O, Joy A A, Harbeck N, Castrellon A, Iyer S, Lu D R, Mori A, Gauthier E R, Bartlett C Huang, Gelmon K A and Slamon D J. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. : Breast cancer research and treatment. 20190716.